Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.40 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.38 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL101958 | 0.87 | CYP1A2 (0.56) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3404089 | 0.84 | CYP1A2 (0.41) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL15959211 | 0.76 | CYP1A2 (0.51) | CYP1A2CYP2C9MAPK1PIK3CAPIK3CD | |
| SCHEMBL29773795 | 0.74 | TRIM24 (0.61) | ALDH1A1GAATRIM24TRIM33KDM4E | |
| SCHEMBL29728417 | 0.72 | CYP1A2 (0.53) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3302627 | 0.72 | CYP1A2 (0.53) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3778169 | 0.71 | CYP1A2 (0.49) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3778174 | 0.71 | CYP1A2 (0.49) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 | |
| SCHEMBL3301348 | 0.71 | CYP1A2 (0.55) | CYP1A2CYP2C9ALDH1A1GAATRIM24 | |
| SCHEMBL3214714 | 0.70 | CYP1A2 (0.51) | CYP1A2CYP2C9ALDH1A1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846687-B2 | Pyrazine compounds as PI3 kinase inhibitors | NOVARTIS AG (CH) | 2014-09-30 | — | — | US | disclosed |
| EP-2597085-A1 | Organic compounds | Novartis AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8268834-B2 | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme | NOVARTIS AG (CH) | 2012-09-18 | — | — | US | disclosed |
| US-20120214800-A1 | Organic Compounds | NOVARTIS AG (CH) | 2012-08-23 | — | — | US | disclosed |
| EP-2257529-A2 | PYRIDINES AND PYRAZINES AS INHIBITORS OF PI3K | Novartis AG (CH) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009115517-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239847-A1 | Organic compounds | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239847-A1 | Organic compounds | AR, TRPA1, IL33 | CYP1A2 94/4885CYP2C9 193/4885ALDH1A1 150/4885 |
| US-20120214800-A1 | Organic Compounds | AR, TRPA1, IL33 | CYP1A2 94/4885CYP2C9 193/4885ALDH1A1 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.